Immunization Strategies Against Acinetobacter baumannii Infections

Acinetobacter baumannii has emerged as a formidable nosocomial pathogen, notable for its rapid acquisition of multidrug and pan-drug resistance. Immunisation strategies against this organism centre on active and passive approaches designed to elicit targeted immune responses that prevent colonisation, limit dissemination and reduce inflammatory pathology. Active immunisation efforts focus on defined antigens such as conserved outer membrane proteins, vesicle-derived components and capsular polysaccharides delivered via subunit formulations, whole-cell preparations or novel delivery vehicles. These vaccines aim to drive high-titre antibody production, mucosal immunity and T-cell-mediated responses, thereby neutralising key virulence factors and promoting opsonophagocytic clearance. Passive immunisation exploits monoclonal or polyclonal antibodies directed against surface structures to afford immediate protection, particularly in critically ill or immunocompromised patients. Across both modalities, adjuvant selection, antigen conservation and route of administration critically influence immunogenicity. As the threat of antimicrobial resistance intensifies globally, effective vaccines and antibody-based prophylactics offer a sustainable means to reduce reliance on dwindling antibiotic options and to curb transmission in healthcare settings.

Research from Nature Portfolio

Investigations into highly conserved outer membrane antigens have yielded promising vaccine candidates. One seminal study characterised a 22-kDa outer membrane protein that is over 95 % conserved among diverse clinical isolates. Active immunisation with this antigen induced robust IgG responses in murine models, resulting in enhanced survival, reduced organ bacterial burdens and suppressed pro-inflammatory cytokine release. Complementary opsonophagocytosis assays confirmed bactericidal activity mediated by antigen-specific sera. In parallel, research on BamA, an essential β-barrel assembly factor, demonstrated that recombinant BamA elicited high IgG titres, with both active and passive immunisation affording significant protection against lethal intranasal challenge. Protection correlated with efficient bacterial clearance from lung tissues and modulation of inflammatory cytokines, underscoring the therapeutic potential of targeting assembly factors critical for membrane integrity.

Immunization Strategies Against Acinetobacter baumannii Infections publication trend

The graph below shows the total number of articles in immunization strategies against acinetobacter baumannii infections across all publications each year (not limited to Nature Index journals).

Technical terms

Outer membrane vesicles (OMVs): Nano-sized blebs shed from the bacterial outer membrane containing proteins, lipids and nucleic acids, used as antigen carriers in vaccine formulations.

Subunit vaccine: A formulation containing one or more purified antigens rather than whole organisms, designed to elicit immune responses with reduced risk of reactogenicity.

Opsonophagocytosis: The process by which antibodies tag pathogens for recognition and ingestion by phagocytic immune cells, leading to microbial killing.

Passive immunization: Administration of preformed antibodies to provide immediate but temporary protection against infection.

Adjuvant: A substance added to a vaccine formulation to enhance and modulate the immune response to co-administered antigens.

References

1. Clinical assays rapidly predict bacterial susceptibility to monoclonal antibody therapy. JCI Insight (2024).
2. Intranasal immunization with outer membrane vesicles (OMV) protects against airway colonization and systemic infection with Acinetobacter baumannii. Journal of Infection (2023).
3. Subunit vaccines for Acinetobacter baumannii. Frontiers in Immunology (2023).
4. Immunization with a 22-kDa outer membrane protein elicits protective immunity to multidrug-resistant Acinetobacter baumannii. Scientific Reports (2016).
5. Immunoprotective potential of BamA, the outer membrane protein assembly factor, against MDR Acinetobacter baumannii. Scientific Reports (2017).